Head and Neck Squamous Cell Carcinoma Market Players:
- Immutep Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Fortress Biotech, Inc.
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Bristol Myers Squibb Company
- AstraZeneca PLC
- Pfizer Inc.
- Boehringer Ingelheim International GmbH
- Checkpoint Therapeutics, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of head and neck squamous cell carcinoma is evaluated at USD 2.54 billion.
The global head and neck squamous cell carcinoma market size was worth around USD 2.35 billion in 2025 and is set to register a CAGR of more than 8.8%, exceeding USD 5.46 billion revenue by 2035.
North America HNSCC market will dominate over 52% share by 2035, driven by the rising frequency of head and neck cancers due to alcohol and tobacco use.
Key players in the market include Immutep Limited, Novartis AG, Fortress Biotech, Inc., F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol Myers Squibb Company, AstraZeneca PLC, Pfizer Inc., Boehringer Ingelheim International GmbH, Checkpoint Therapeutics, Inc.
